Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Outcomes associated with bacteremia in the setting of
methicillin-resistant Staphylococcus aureus pneumonia: A
retrospective cohort study
Andrew F. Shorr
Washington Hospital Center

Marya D. Zilberberg
University of Massachusetts - Amherst

Scott T. Micek
St. Louis College of Pharmacy

Marin H. Kollef
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Shorr, Andrew F.; Zilberberg, Marya D.; Micek, Scott T.; and Kollef, Marin H., ,"Outcomes associated with
bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: A retrospective
cohort study." Critical Care. 19,. 312. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4194

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Shorr et al. Critical Care (2015) 19:312
DOI 10.1186/s13054-015-1029-z

RESEARCH

Open Access

Outcomes associated with bacteremia in the
setting of methicillin-resistant Staphylococcus
aureus pneumonia: a retrospective cohort study
Andrew F. Shorr1*, Marya D. Zilberberg2,3, Scott T. Micek4 and Marin H. Kollef5

Abstract
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in pneumonia.
Bacteremia may secondarily complicate MRSA pneumonia. The epidemiology and outcomes associated with
bacteremia in the setting of MRSA pneumonia are unknown. We sought to describe the prevalence of bacteremia
in MRSA pneumonia and its impact on hospital mortality and length of stay (LOS).
Methods: We conducted a single-center retrospective cohort study (2008–2013) including adult patients
hospitalized with pneumonia caused by MRSA. We defined pneumonia based on clinical criteria and all cases were
culture confirmed. MRSA bacteremia was identified based on positive blood cultures. Pneumonia was categorized
as either community-onset (CO, occurring at presentation or within 2 days of admission) or hospital-onset
(HO, occurring > 2 days after admission). We compared bacteremic and non-bacteremic groups with respect to
their demographic and clinical characteristics and outcomes. A logistic regression and a generalized linear model
(GLM) were constructed to examine the impact of bacteremia on hospital mortality and post-pneumonia onset
LOS, respectively.
Results: Among the 765 patients with MRSA pneumonia (33.1 % CO), 93 (12.2 %) had concurrent bacteremia
(37.6 % CO). Patients with bacteremia were similar to non-bacteremic subjects based on demographic and clinical
characteristics with the exception of frequency of a hospitalization within prior 180 days (48.4 % bacteremic and
37.7 % non-bacteremic, p = 0.047), prevalence of chronic liver disease (17.2 % vs. 9.5 %, p = 0.030), and the mean
APACHE II score at the onset of pneumonia (17.5 ± 6.0 vs. 16.1 ± 6.0, p = 0.045). Both unadjusted mortality
(33.7 % vs. 23.8 %, p = 0.067) and median post-pneumonia LOS (18.2 vs. 12.2 days, p < 0.001) were greater in the
bacteremic than the non-bacteremic group. In a logistic regression, bacteremia showed a trend toward an
association with increased mortality (odds ratio 1.56, 95 % confidence interval 0.93 to 2.61). Concomitant
bacteremia was independently associated with a 10.3-day increase in the post-pneumonia hospital LOS
(95 % confidence interval 6.7 to 13.9 days).
Conclusions: Concurrent bacteremia occurred with moderate frequency in the setting of hospitalization with MRSA
pneumonia. Although bacteremia did not appear to independently impact mortality, this was likely due to our
study’s limited sample size. However, bacteremia complicating MRSA pneumonia added between 1 and 2 weeks to
the hospital LOS.
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Introduction
Rates of infection due to methicillin-resistant Staphylococcus aureus (MRSA) have been falling over the last 5 years
in both the United States and in Europe [1]. Despite this
trend, MRSA remains an important cause of pneumonia
and is associated with substantial morbidity and mortality.
Specifically, MRSA has been implicated as a pathogen in
healthcare-associated (HCAP), hospital-acquired (HAP),
and ventilator-associated (VAP) pneumonia [2]. In VAP in
the US, for example, MRSA represents the second most
common bacterial etiology for this infection [3]. More importantly, crude in-hospital mortality rates in these various MRSA pulmonary infections range from 10 to 30 %
[3, 4]. Furthermore, in the US the community-associated
strain of MRSA has been reported to be occasionally a
cause of community-acquired pneumonia (CAP) and to
lead to severe necrotizing infections [5]. In Europe,
although MRSA rates have declined rapidly, MRSA pneumonia continues to result in poor outcomes, and several
European experts have proposed MRSA pneumonia
guidelines to address this syndrome [6, 7].
Significant predictors of survival in MRSA pneumonia
include the timeliness of antibiotic therapy, severity of
illness at time of infection onset, and chronic underlying
conditions [8, 9]. Less certain is the importance of concurrent bacteremia in MRSA pneumonia. In skin and
skin structure infections caused by MRSA, secondary
bacteremia appears to occur in up to 10 % of patents,
but has no impact on mortality [8, 10]. With respect to
MRSA pneumonia, little is known about the prevalence
of bacteremia complicating this infection, as few reports
have analyzed this systematically. Those analyses that
have addressed bacteremia in MRSA pneumonia have,
generally, been small [11, 12]. Additionally, no information
exists regarding whether and how concurrent bacteremia
in MRSA pneumonia affects hospital length of stay (LOS),
a major determinant of healthcare costs.
In order to clarify these issues, we conducted a retrospective analysis of all patients with MRSA pneumonia
treated at a large, tertiary-care hospital. Specifically,
we sought to determine the prevalence of concurrent
bacteremia in MRSA pneumonia. Moreover, we aimed
to describe the impact of bacteremia on both hospital
mortality and hospital LOS.
Methods
Study overview

We retrospectively evaluated all subjects with MRSA
pneumonia admitted to a single institution (Barnes-Jewish
Hospital, St. Louis, MO, USA) between December 2008
and December 2013. The study only included adult patients (aged > 18 years) admitted through the emergency
department. We excluded those persons transferred
directly to the hospital from other institutions. We
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also excluded patients with polymicrobial respiratory
infections. This project was approved by the BarnesJewish Hospital institutional review board, and there
was no requirement for informed consent given our
retrospective design.
Pneumonia was identified based on traditional signs
and symptoms of chest infection. We further required
evidence of an infiltrate on chest imaging (e.g., either
chest radiograph or computed tomographic scan). All
radiology studies were reviewed by a single investigator
(M.H.K.). Cases were initially identified for possible
inclusion in the study cohort through a review of an
administrative database of all persons with a discharge
diagnosis of any type of pneumonia or of sepsis and
respiratory failure. These results were cross-referenced
with the hospital’s microbiology system to identify all
individuals with positive respiratory and blood cultures
showing MRSA (as described below). To be included,
patients must have had a respiratory culture which grew
MRSA along with the appropriate signs and evidence of
pneumonia. Subjects with abnormal chest imaging and
blood cultures revealing MRSA but in whom respiratory
cultures revealed no growth were excluded.
End points

In hospital, all-cause mortality served as the primary end
point. Hospital LOS following the infection onset represented a secondary end point.
Definitions and variables

Pneumonia was classified as CAP or HCAP if it was
diagnosed within 2 days of hospitalization. In contrast,
pneumonia was deemed HAP or VAP if it occurred 3 or
more days following admission to the hospital and was
not present on admission. VAP specifically required the
patient to be on mechanical ventilation for at least 24
hours prior to the infection’s onset. We defined pneumonia as due to MRSA if sputum, lower airway, blood, or
pleural cultures were positive for MRSA. Patients without
a respiratory culture revealing MRSA were excluded. We
further ascertained if bacteremia complicated the patient’s
pneumonia. We defined bacteremia as present if at least
one blood culture was positive for MRSA. Only blood cultures drawn within 48 hours of the onset of pneumonia
were reviewed in order to ensure that the pneumonia and
bacteremia were concurrent events. As part of institutional protocol, all subjects with suspected pneumonia
undergo routine blood culture sampling (Bactec system,
Becton Dickson, Franklin Lakes, NJ, USA). We examined
a number of covariates, such as demographic variables
(age, sex, race), chronic disease burden (as individual comorbidities as well as their global burden as represented
by the Charlson score), acute illness severity (Acute Physiology and Chronic Health Evaluation [APACHE] II score,
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need for mechanical ventilation and/or vasopressors), laboratory, physiological and treatment parameters [13, 14].
Statistical analyses

Continuous variables were reported as means with
standard deviations and as medians with 25th and 75th
percentiles. Differences between mean values were tested
via the Student’s t test, while those between medians
were examined using the Mann-Whitney U test. Categorical data were summarized as proportions, and the
chi-square test or Fisher’s exact test for small samples
was used to examine differences between groups. We
developed several multiple logistic regression models to
identify clinical risk factors for hospital mortality. In the
mortality models, all risk factors that were significant at
≤ 0.20 in the univariate analyses, as well as all biologically plausible factors, even if they did not reach this level
of significance, were included in the corresponding multivariable analyses. All variables entered into the models
were examined for collinearity, and interaction terms
were tested. The most parsimonious models were derived using the backward manual elimination method,
and the best-fitting model was chosen based on the area
under the receiver operating characteristics curve
(AUROC or the c-statistic). The model’s calibration was
assessed with the Hosmer-Lemeshow goodness-of-fit test.
To examine the determinants of bacteremia-attributable
LOS, we constructed a generalized linear model (GLM)
with log-link to a Gaussian distribution. Model fit was
tested using Akaike information criterion (AIC) and
Bayesian information criterion (BIC) tests. All tests were
two-tailed. Because of sample size considerations, a p
value < 0.10 was deemed acceptable a priori to represent statistical significance for the mortality outcome.
All remaining tests of significance required alpha < 0.05.
All computations were performed in Stata/SE, version 9
(StataCorp, College Station, TX, USA).

Results
Among the 765 patients with MRSA pneumonia (33.1 %
CAP/HCAP), 93 (12.2 %) had concurrent bacteremia. At
baseline, patients with bacteremia were similar to nonbacteremic subjects based on demographic and clinical
characteristics with the exception of frequency of a
hospitalization within the prior 180 days (48.4 % bacteremic and 37.7 % non-bacteremic, p = 0.047) and prevalence of chronic liver disease (17.2 % vs. 9.5 %, p = 0.030)
(Table 1). Reflecting this, the mean Charlson comorbidity
scores were 4.4 ± 3.3 and 4.2 ± 3.4 among bacteremic and
non-bacteremic patients, respectively, p = 0.340. At the
onset of pneumonia, while the mean APACHE II score
was higher among bacteremic subjects (17.5 ± 6.0 vs.
16.1 ± 6.0, p = 0.045), no significant differences were
observed between the groups in the rates of either

Page 3 of 10

mechanical ventilation or vasopressor requirements
(Table 2). The median creatinine clearance (CrCl), however, was lower in the setting of bacteremia than in its absence (48, interquartile range [IQR] 26–67 vs. 56, IQR
33–79, p = 0.019). The most common initial antibiotic in
both the bacteremic and non-bacteremic subjects was
vancomycin, which was administered to nearly 80 % of
subjects empirically. The median time to first anti-MRSA
antibiotic administration appropriate for suspected pneumonia (i.e., vancomycin or linezolid) in both arms was less
than 2 hours (Table 2).
Unadjusted mortality (33.7 % vs. 23.8 %, p = 0.067)
and median post-pneumonia LOS (18.2 vs. 12.2 days,
p < 0.001) were greater in the bacteremic than the
non-bacteremic group (Table 3, Fig. 1). There were no
differences in the discharge destination, with the proportion discharged to home as opposed to a nursing home
similar between the groups.
In a logistic regression, bacteremia showed a trend toward an association with increased mortality at the alpha
level of 0.050, (odds ratio 1.56, 95 % confidence interval
[CI] 0.93 to 2.61), and was significantly associated with it
at the level of p < 0.100 (90 % CI 1.01 to 2.40) (Table 4).
Other variables associated with an increased risk of death
included measures of disease severity such as the need for
mechanical ventilation and the APACHE II score. This
model demonstrated a good fit with a Hosmer-Lemeshow
p = 0.910 and an AUROC of 0.75. Concomitant bacteremia was independently associated with a 10.3-day increase in the attributable post-pneumonia onset hospital
LOS (95 % CI 6.7 to 13.9 days, p < 0.001) (Table 5). This
model for attributable LOS also had a good fit with an
AIC of 8.35. Pneumonia type, which was entered into the
model, was not retained in the final model as a significant
predictor.

Discussion
This large retrospective analysis indicates that bacteremia
complicates nearly one in seven cases of MRSA pneumonia. Although we failed to note an independent impact of
secondary bacteremia on hospital mortality, this likely reflects our limited sample size rather that a true absence of
an effect. In addition, MRSA bacteremia as a component
of MRSA pneumonia adds to the attributable LOS and
thus increases hospital costs.
Prior efforts to address the importance of concurrent
bacteremia in MRSA pneumonia have been limited. In
an analysis of approximately 600 patients with either
nosocomial pneumonia or VAP, Magret and coworkers
noted that bacteremia occurred in 15 % of subjects,
similar to the rate we report. [15] Magret et al., though,
included all subjects with either HAP or VAP, irrespective
of pathogen [15]. In fact, MRSA accounted for less than
16 % of their study cohort. Nonetheless, they observed
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Table 1 Baseline characteristics
Bacteremia −

Bacteremia +

P value

N

%

N

%

93

12.16 %

672

87.84 %

Age, yrs
Mean [SD]

58.4 [14.1]

58.8 [17.8]

Median (IQR)

58.5 (53.4, 67.6)

60.8 (48.1, 72.3)

0.622

Race
Caucasian

51

54.84 %

424

63.10 %

African-American

39

41.94 %

213

31.70 %

Asian

0

0.00 %

5

0.74 %

Other

0

0.00 %

6

0.89 %

Unknown

3

3.23 %

24

3.57 %

Gender, female

35

37.63 %

290

43.15 %

0.392

0.580

BMI
Mean [SD]

28.6 [9.1]

Median (IQR)

27.5 (21.9, 33.5)

Hospitalization in previous 180 days

29.0 [10.1]
26.9 (22.2, 33.3)

0.941

45

48.39 %

253

37.65 %

0.047

MI

12

12.90 %

74

11.01 %

0.599

CHF

21

22.58 %

140

20.83 %

0.685

PVD

13

13.98 %

82

12.20 %

0.616

CVD

11

11.83 %

74

11.01 %

0.860

Dementia

3

3.23 %

11

1.64 %

0.237

Comorbidities

COPD

30

32.26 %

210

31.25 %

0.905

Connective tissue disease

2

2.15 %

22

3.27 %

0.757

PUD

6

6.45 %

24

3.57 %

0.246

CLD

16

17.20 %

64

9.52 %

0.030

DM

25

26.88 %

158

23.51 %

0.517

CKD

20

21.51 %

99

14.73 %

0.095

CA
HIV

19

20.43 %

142

21.13 %

1.000

1

1.08 %

4

0.60 %

0.478

Charlson score
Mean [SD]

4.4 [3.3]

4.2 [3.4]

Median (IQR)

4 (2, 6)

3 (1, 6)

0.340

SD standard deviation, IQR interquartile range, BMI body mass index, MI myocardial infarction, CHF congestive heart failure, PVD peripheral vascular disease, CVD
cerebrovascular disease, COPD chronic obstructive pulmonary disease, PUD peptic ulcer disease, CLD chronic liver disease, DM diabetes mellitus, CKD chronic
kidney disease, CA cancer, HIV human immunodeficiency virus

that concurrent MRSA bacteremia independently correlated with a higher risk for death. Exploring the issue of
the interaction between pneumonia and bloodstream infection from a different perspective, Turnidge et al. analyzed predictors of mortality in a cohort of nearly 2000
patients with S. aureus bacteremia, including both those
with methicillin-susceptible S. aureus and MRSA infection
[16]. Persons with concurrent pneumonia and bacteremia
only comprised a small aspect of their population (7.8 %)

[16]. Pneumonia as the primary infection site, though, appeared to confer a higher risk for death.
In one of the larger efforts to describe variables associated with mortality in MRSA pneumonia, Haque and
colleagues analyzed 251 cases of MRSA pneumonia [12].
As others have shown, severity of illness was the main
driver of outcomes. However, they failed to even examine concurrent bacteremia as a potential factor affecting
eventual survival [12]. Finally, Schreiber et al. specifically
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Table 2 Pneumonia and treatment characteristics
Bacteremia −

Bacteremia +

P value

N

%

N

%

93

12.16 %

672

87.84 %

Pneumonia characteristics
Pre-pneumonia LOS, days
Mean [SD]

11.3 [15.0]

8.6 [13.7]

Median (IQR)

4.7 (1.1, 15.8)

4.6 (0.9, 11)

ICU prior to pneumonia

15

16.13 %

94

0.333
13.99 %

0.634

0.318

Pneumonia type
CAP or HCAP

35

37.63 %

218

32.44 %

HAP or VAP

58

62.37 %

454

67.56 %

ICU at onset of pneumonia

66

70.97 %

485

72.17 %

0.806

ICU transfer after pneumonia onset

5

5.38 %

19

2.83 %

0.198

No ICU during pneumonia admission

7

7.53 %

73

10.86 %

0.372

Bronchial brushing

0

0.00 %

1

0.15 %

0.565

Bronchial washing

8

8.60 %

33

4.91 %

Bronchoalveolar lavage

7

7.53 %

55

8.18 %

Sputum

7

7.53 %

73

10.86 %

Induced sputum

4

4.30 %

23

3.42 %

Tracheal aspirate

67

72.04 %

487

72.47 %

Mechanical ventilation

71

76.34 %

499

74.26 %

0.705

Vasopressors

40

43.01 %

228

33.93 %

0.104

Specimen type

Illness severity

APACHE II (at pneumonia onset)
Mean [SD]

17.5 [6.0]

16.1 [6.0]

Median (IQR)

16 (13, 22)

16 (12, 20)

Mean [SD]

15.4 [7.2]

15.3 [12.5]

Median (IQR)

14.2 (10.5, 21.2)

13.5 (10, 17.9)

0.045

Day of pneumonia onset peak WBC

0.232

Day of pneumonia onset peak temperature, C
Mean [SD]

38.1 [1.1]

38.1 [1.0]

Median (IQR)

38.2 (37.5, 38.9)

38.2 (37.3, 38.8)

0.834

50.78 ± 31.42

58.84 ± 32.44

0.019

CrCl (at pneumonia onset)
Mean [SD]
Median (IQR)
CrCl > 50 (at pneumonia onset)

48 (26, 67)
43

56 (33, 79)
46.24 %

379

56.40 %

0.065

Treatment characteristics
Time to first drug, hrs
Mean [SD]

8.7 [21.7]

17.6 [41.7]

Median (IQR)

0.1 (0.1, 4.0)

0.1 (0.1, 18.6)

0.007
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Table 2 Pneumonia and treatment characteristics (Continued)
Drug
Ceftaroline

6

6.45 %

12

1.79 %

0.015

Daptomycin

13

13.98 %

13

1.93 %

<0.001

Linezolid

47

50.54 %

219

32.59 %

0.001

Vancomycin

83

89.25 %

559

83.18 %

0.174

Time to drug, hrs
Ceftaroline
Mean [SD]

582.7 [562.5]

382.1 [653.6]

Median (IQR)

448.9 (69.6, 1,180.5)

150.2 (16.6, 440.5)

0.426

Daptomycin
Mean [SD]

172.7 [252.0]

648.7 [874.6]

Median (IQR)

54.3 (0.1, 187.7)

430.4 (236.7, 580)

Mean [SD]

117.3 [171.9]

138.9 [225.8]

Median (IQR)

46.5 (12.2, 157.7)

67.3 (23.0, 170.8)

Mean [SD]

0.9 [0.3]

0.8 [0.4]

Median (IQR)

1 (1, 1)

1 (1, 1)

0.017

Linezolid

0.280

Vancomycin

0.110

Number of anti-MRSA drugs used
0

5

5.38 %

85

12.65 %

1

36

38.71 %

386

57.44 %

2

43

46.24 %

187

27.83 %

3

9

9.68 %

13

1.93 %

4

0

0.00 %

1

15.00 %

<0.001

LOS length of stay, SD standard deviation, IQR interquartile range, ICU intensive care unit, CAP community-acquired pneumonia, HCAP healthcare-associated
pneumonia, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia, APACHE Acute Physiology and Chronic Health Evaluation, WBC white blood
cells, CrCl creatinine clearance, MRSA methicillin-resistant Staphylococcus aureus

explored the potential significance of secondary bacteremia in MRSA pneumonia. They concluded that
bacteremia was seen in 20 % of cases of MRSA pneumonia and that bacteremia independently increased the risk
for death sixfold. However, this analysis included only 59
subjects and enrolled both those with MRSA and MRSA
pneumonia [11]. Reflecting concerns about the seriousness of MRSA as a cause of pneumonia, some have proposed specific MRSA pneumonia treatment paradigms
based on the presence or absence of bacteremia, and our
results demonstrate the importance of this confounding
issue (6.7).
Our study expands on these earlier reports. We confirm
a general association between concomitant bacteremia
and worse outcomes in MRSA pneumonia. Unlike prior
analyses, we evaluated a large cohort of MRSA pneumonia. Furthermore, our cohort was fairly heterogeneous in
that it included all cases of MRSA pneumonia, irrespective
of pneumonia subtype (e.g., HCAP vs. VAP). This fact
helps to establish the generalizability of our findings. The
relatively large sample size additionally allows us to better

control for a variety of confounders that others could not
address as fully. We also establish that concurrent
bacteremia adds substantially to hospital LOS. This observation is novel as others have not examined this issue previously. The deleterious impact on LOS is independent of
multiple potential confounders. Given that bacteremia remains associated with a greater LOS, our findings suggest
that future studies should focus on this cohort of patients
in order to determine if some different treatment paradigm might mitigate the negative impact of concurrent
bacteremia on LOS. Finally, all patients in this report
received timely therapy, reducing the risk that an initial
delay in antibiotic treatment confounds our conclusions.
Why might the simultaneous presence of MRSA pneumonia and bacteremia lead to worse patient outcomes?
Host factors such as underlying comorbidities could explain some of this connection. For example, patients
with bacteremia were more likely to suffer from liver
disease than those whose pneumonia was not complicated by bacteremia. However, it seems unlikely that
chronic host issues alone account for the excess burden
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Table 3 Unadjusted outcomes
Bacteremia −

Bacteremia +

P value

N

%

N

%

93

12.16 %

672

87.84 %

Post-pneumonia onset LOS, days
Mean [SD]

25.8 [26.6]

15.8 [16.0]

Median (IQR)

18.2 (8.1, 31.3)

12.2 (6.1, 19.9)

<0.001

Total LOS, days
Mean [SD]

37.1 [33.5]

24.4 [22.8]

Median (IQR)

29.5 (12.8, 46.1)

18.3 (9.9, 31.2)

<0.001

Discharge destination
Home

6

6.45 %

84

12.50 %

Rehab

13

13.98 %

97

14.43 %

LTAC

13

13.98 %

62

9.23 %

SNF

19

20.43 %

134

19.94 %

Home with home health services

7

7.53 %

106

15.77 %

a

Other

4

4.30 %

31

4.61 %

Died during hospitalization

31

33.70 %

158

23.80 %

Died during hospitalization or sent home with hospice care

32

34.41 %

165

24.55 %

0.067

0.042

LOS length of stay, SD standard deviation, IQR interquartile range, LTAC long-term acute care, SNF skilled nursing facility
a
Category of discharge “other” includes: against medical advice (n = 4), home with hospice care (n = 8), licensed nursing facility (n = 1), psychiatric unit (n = 1),
federal hospital (n = 7), other short-term hospital (n = 5), missing (n = 9)

of bacteremia. The absence of any baseline host factors
in either the mortality or LOS models indicates that
these types of variables likely contribute little to overall
outcomes. Alternatively, bacteremia might lead to more
severe illness. The presence of bacteria in the blood
could theoretically potentiate a cytokine cascade resulting in a more robust systemic inflammatory response.
Conversely, bacteremia might simply reflect poor initial

source control and a greater organism burden. In either
event, the effect of secondary bacteremia on outcomes
in MRSA pneumonia likely arises due a complex interaction between the host and the pathogen. However, this
relationship is likely more complex than our current
tools allow us to elucidate. Haque et al., for instance, analyzed a number of variables related to the bacteria to
include its SECmec type, pulsed-field gel electropheresis

Fig. 1 Plot of post-pneumonia onset LOS stratified by bacteremia. LOS length of stay
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Table 4 Predictors of mortality
Parameter

OR

95 % CI

90 % CI

P value

Mechanical ventilation

3.18

1.79 to 5.64

1.96 to 5.14

0.001

Bacteremia

1.56

0.93 to 2.61

1.01 to 2.40

0.091

Vasopressors

1.46

1.01 to 2.12

1.07 to 2.00

0.047

APACHE II (per 1 point)

1.09

1.06 to 1.13

1.06 to 1.12

<0.001

Day of pneumonia onset peak T, C (per 0.1 degree)

0.76

0.63 to 0.92

0.65 to 0.89

0.004

ICU prior to pneumonia

0.29

0.14 to 0.61

0.16 to 0.54

0.001

AUROC = 0.750
Hosmer-Lemeshow goodness-of-fit p = 0.910
-Factors included but not retained at the p value of < 0.1:
Age, BMI, CAP/HCAP, day of pneumonia onset peak WBC, peak WBC over 7 days after pneumonia onset, CrCl > 50
-Factors excluded for perfect prediction:
ICU transfer after pneumonia onset, no ICU during pneumonia admission
-Factors excluded for collinearity:
Charlson, pre-pneumonia LOS, ICU at onset of pneumonia
OR odds ratio, CI confidence interval, APACHE Acute Physiology and Chronic Health Evaluation, ICU intensive care unit, AUROC area under the receiver operating
curve, BMI body mass index, CAP community-acquired pneumonia, HCAP healthcare-associated pneumonia, WBC white blood cells, CrCl creatinine clearance, LOS
length of stay

type, Panton-Valentine leukocidin toxin gene presence
and their connection with mortality in MRSA pneumonia [12]. None of these aspects of the culprit MRSA
appeared to alter mortality in MRSA pneumonia. Furthermore, the longer LOS may reflect, in part, the choices
used to treat patients with concurrent bacteremia. With
bacteremia nearly all patients received intravenous glycopeptides. As such, this may have either prolonged
hospitalization as outpatient antibiotic therapy was arranged or because outpatient infusion was not an option
in select cases. Our findings, hence, may reflect an issue
with the choices we have for this serious disease as opposed to some aspect of the bacteremia itself. However,
even if this possibility explains some of the difference in
LOS between those with and those lacking bacteremia,
our data continue to represent a “real world” assessment
of the burden of bacteremia in MRSA pneumonia.

Table 5 Attributable hospital length of stay in days
Parameter

Point estimate

95 % CI

P value

Bacteremia

10.3

6.7 to 13.9

<0.001

Mechanical ventilation

6.8

3.8 to 9.8

<0.001

Vasopressors

5.6

3.0 to 8.1

<0.001

Time from admission to
pneumonia onset (per 1 day)

0.11

0.06 to 0.15

<0.001

Time to anti-MRSA treatment
(per 1 hour)

0.03

0.01 to 0.05

0.002

In-hospital mortality

−5.8

−8.4 to −3.2

<0.001

AIC = 8.35
BIC = 156153.9
CI confidence interval, MRSA methicillin-resistant Staphylococcus aureus

Our study has a number of significant limitations.
First, its retrospective design opens it to various forms
of bias. Specifically, selection bias certainly may have affected our findings. Similarly, ascertainment bias in the
identification of bacteremias, due to both the limitations
of blood cultures and the frequency with which they are
drawn, likely plays a role in our findings. However, we
focused on end points such as mortality and LOS, which
are not prone to ascertainment or recall bias. We also
lacked consistent data on several variables such as the
post-infection onset duration of mechanical ventilation.
Second, the data derive from a single center and this necessarily limits the generalizability of our findings. In
that same vein, the vast majority of our subjects received
vancomycin for initial therapy. As such, our results may
not be reflective of what one might see if other agents
had been employed empirically. Third, despite being a
rather large cohort, we nevertheless may have lacked
power to adjust for certain confounders that could affect
either of our end points. Furthermore, pneumonia itself
can represent a difficult diagnosis. To address this concern we utilized precise criteria for the diagnosis of pulmonary infection and had one reviewer examine all
chest imaging studies. Fourth, nearly every patient in the
study was given vancomycin initially. It remains unclear
if vancomycin represents the optimal choice for MRSA
pneumonia and therefore our findings might have been
different if subjects were treated with other alternative
options. With respect to vancomycin, also, we lack data
about trough levels. Hence our results may have been
skewed by inappropriate dosing even if patients received
timely antibiotics. Fifth, given that in some cases patients
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could have had multiple primary infections occurring
concurrently (e.g., a catheter-associated bloodstream infection and a pneumonia) that were misconstrued as one
diagnosis, we may have overestimated the frequency of
bacteremia complicating MRSA pneumonia. Finally, we
could not classify MRSA isolates as to their genotypes
(e.g., USA 300 vs. USA 400 strains). Historically in our
hospital, USA 300 has been a rare cause of any type of
pneumonia. Hence the results we report may not be applicable to settings where the USA 300 strain is far more
prevalent.

Conclusions
In conclusion, concurrent bacteremia in MRSA pneumonia appeared to occur with moderate frequency. Although bacteremia’s impact on mortality did not reach
statistical significance at alpha < 0.05, this was likely due
to our study’s limited sample size. However, bacteremia
complicating MRSA pneumonia added between 1 and 2
weeks to the hospital LOS.
Key messages
 Concurrent bacteremia occurred in 12 % of

intensive care unit (ICU) patients with MRSA
pneumonia
 There was a trend toward increased hospital
mortality among patients with concurrent
bacteremia compared to those without
 Concurrent bacteremia in the setting of MRSA
pneumonia was associated with an increase in the
hospital LOS of 1–2 weeks
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